Nasdaq · CIK 0000879407
ARWR ARROWHEAD PHARMACEUTICALS, INC.
Insider trading from SEC Form 4. Last filing Aug 20, 2026. Close $62.75 on Oct 9, 2026, +77% from the 52-week low and -30% from the high.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has 56 SEC Form 4 filings on file from 13 insiders, the latest filed on Aug 20, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 2 open-market sells worth $1.2M, net -$1.2M.
37 open-market trades have been scored at ARWR. The newest: Adeoye Y Olukotun (director) sold $174k of stock on Aug 18, 2026, filed Aug 20, 2026, scored 34 (weak). The largest of the 37 shown: Christopher Richard Anzalone (Chief Executive Officer) sold $12M on Dec 15, 2025, scored 65 (notable). 2 insiders sold within 14 days of each other around Aug 18, 2026.
ARWR closed at $62.75 on Oct 9, 2026, 77% above its 52-week low and 30% below its 52-week high.
25 Form 144 notices of planned sales are on file, the latest filed Aug 18, 2026.
Last 90 days
Net insider value
-$1.2M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
2
$1.2M by 2 insiders
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
ARWROct 9, 2026 · close 62.75
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ARROWHEAD PHARMACEUTICALS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 34Weak | Adeoye Y Olukotun director sell | $174k 2,000 shares | -6% | +343% from low-2% from high | |
| 48Moderate | Michael S Perry director sell | $1.0M 11,600 shares | -9% | +343% from low-2% from high | |
| 8Weak | Hongbo Lu director sell | $228k 2,970 shares | -5% | +466% from low-0% from high | |
| 34Weak | Daniel Joseph Apel Chief Financial Officer sell | $934k 13,095 shares | -7% | +498% from low0% from high | |
| 25Weak | James C Hamilton Chief Medical Officer sell | $750k 10,000 shares | -4% | +472% from low0% from high | |
| 15Weak | James C Hamilton Chief Medical Officer sell | $642k 10,000 shares | -4% | +537% from low-13% from high | |
| 43Moderate | Christopher Richard Anzalone Chief Executive Officer sell | $872k 13,187 shares | -0% | +579% from low-4% from high | |
| 40Moderate | Patrick O'Brien COO sell | $3.1M 49,493 shares | -9% | +539% from low-10% from high | |
| 40Moderate | James C Hamilton Chief Medical Officer sell | $2.5M 40,164 shares | -19% | +539% from low-10% from high | |
| 30Weak | Christopher Richard Anzalone Chief Executive Officer sell | $3.6M 51,726 shares | -1% | +597% from low-2% from high | |
| 28Weak | Mauro Ferrari director sell | $527k 7,530 shares | -10% | +602% from low-1% from high | |
| 35Weak | Adeoye Y Olukotun director sell | $677k 10,000 shares | -23% | +582% from low-4% from high | |
| 45Moderate | Christopher Richard Anzalone Chief Executive Officer sell | $1.8M 26,031 shares | -1% | +582% from low-4% from high | |
| 34Weak | William D. Waddill director sell | $566k 8,367 shares | -13% | +582% from low-4% from high | |
| 36Weak | Victoria Vakiener director sell | $679k 10,040 shares | -22% | +582% from low-4% from high | |
| 65Notable | Christopher Richard Anzalone Chief Executive Officer sell | $5.4M 85,000 shares | -2% | +549% from low-9% from high | |
| 65Notable | Christopher Richard Anzalone Chief Executive Officer sell | $12M 184,298 shares | -4% | +585% from low-3% from high | |
| 60Notable | Michael S Perry director sell | $992k 16,250 shares | -12% | +515% from low-6% from high | |
| 46Moderate | Mauro Ferrari director sell | $493k 8,750 shares | -11% | +428% from low-9% from high | |
| 16Weak | James C Hamilton Chief Medical Officer sell | $700k 20,000 shares | -9% | +250% from low0% from high | |
| 12Weak | James C Hamilton Chief Medical Officer sell | $450k 15,000 shares | -6% | +198% from low0% from high | |
| 11Weak | James C Hamilton Chief Medical Officer sell | $375k 15,000 shares | -6% | +157% from low-3% from high | |
| 7Weak | James C Hamilton Chief Medical Officer sell | $200k 10,000 shares | -4% | +100% from low-24% from high | |
| 50Moderate | Christopher Richard Anzalone Chief Executive Officer sell | $1.5M 141,122 shares | -3% | +18% from low-55% from high | |
| 47Moderate | Christopher Richard Anzalone Chief Executive Officer sell | $775k 51,425 shares | -1% | +0% from low-43% from high | |
| 15Weak | Christopher Richard Anzalone Chief Executive Officer sell | $5.3M 300,000 shares | -7% | +0% from low-33% from high | |
| 0Weak | Adeoye Y Olukotun director sell | $20k 959 shares | -3% | +22% from low-18% from high | |
| 41Moderate | Kenneth Allen Myszkowski Chief Financial Officer sell | $893k 45,167 shares | -9% | +10% from low-26% from high | |
| 36Weak | Patrick O'Brien COO and General Counsel sell | $736k 37,184 shares | -7% | +10% from low-26% from high | |
| 35Weak | James C Hamilton Chief Discovery/Trans Medicine sell | $649k 32,729 shares | -11% | +10% from low-26% from high | |
| 32Weak | Christopher Richard Anzalone Chief Executive Officer sell | $219k 11,520 shares | -0% | +11% from low-25% from high | |
| 17Weak | Adeoye Y Olukotun director sell | $57k 2,850 shares | -7% | +7% from low-28% from high | |
| 33Weak | Christopher Richard Anzalone Chief Executive Officer sell | $246k 12,563 shares | -0% | +12% from low-25% from high | |
| 39Weak | Christopher Richard Anzalone Chief Executive Officer sell | $567k 26,712 shares | -1% | - | |
| 32Weak | Victoria Vakiener director sell | $197k 8,994 shares | -30% | - | |
| 20Weak | Douglas B Given director sell | $122k 5,547 shares | -4% | - | |
| 26Weak | William D. Waddill director sell | $165k 7,495 shares | -16% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 18, 2026 | Michael Perry Director | 11,600 0.01% of outstanding | $1.0M | Aug 18, 2026 | none |
| Aug 18, 2026 | Adeoye Olukotun Director | 2,000 0.00% of outstanding | $174k | Aug 18, 2026 | none |
| May 12, 2026 | Hongbo Lu Officer | 2,970 0.00% of outstanding | $228k | May 12, 2026 | none |
| Apr 23, 2026 | James Hamilton Officer | 10,000 0.01% of outstanding | $750k | Apr 23, 2026 | $642k |
| Apr 22, 2026 | Daniel Apel Officer | 13,095 0.01% of outstanding | $934k | Apr 22, 2026 | none |
| Mar 5, 2026 | James Hamilton Officer | 10,000 0.01% of outstanding | $642k | Mar 5, 2026 | $2.5M |
| Jan 5, 2026 | Patrick O'Brien Officer | 49,493 0.04% of outstanding | $3.1M | Jan 5, 2026 | none |
| Jan 5, 2026 | James Hamilton Officer | 39,728 0.03% of outstanding | $2.5M | Jan 5, 2026 | none |
| Jan 2, 2026 | Christopher Anzalone Officer | 13,187 0.01% of outstanding | $872k | Jan 2, 2026 | $23M |
| Dec 29, 2025 | Mauro Ferrari Director | 7,530 0.01% of outstanding | $527k | Dec 26, 2025 | $493k |
| Dec 29, 2025 | Christopher Anzalone Officer | 51,726 0.04% of outstanding | $3.6M | Dec 29, 2025 | $20M |
| Dec 22, 2025 | Christopher Anzalone Officer | 12,586 0.01% of outstanding | $861k | Dec 22, 2025 | $19M |
| Dec 19, 2025 | Victoria Vakiener Director | 10,040 0.01% of outstanding | $679k | Dec 19, 2025 | none |
| Dec 19, 2025 | Adeoye Olukotun Director | 10,000 0.01% of outstanding | $677k | Dec 19, 2025 | none |
| Dec 19, 2025 | William Waddill Director | 8,367 0.01% of outstanding | $566k | Dec 19, 2025 | none |
| Dec 19, 2025 | Christopher Anzalone Officer | 13,445 0.01% of outstanding | $910k | Dec 19, 2025 | $18M |
| Dec 17, 2025 | Christopher Anzalone Officer | 85,000 0.06% of outstanding | $5.4M | Dec 17, 2025 | $12M |
| Dec 16, 2025 | Christopher Anzalone Officer | 54,298 0.04% of outstanding | $3.4M | Dec 16, 2025 | $9.0M |
| Dec 15, 2025 | Christopher Anzalone Officer | 130,000 0.10% of outstanding | $9.0M | Dec 15, 2025 | none |
| Dec 5, 2025 | Michael Perry Director | 16,250 0.01% of outstanding | $991k | Dec 5, 2025 | none |
| Nov 28, 2025 | Mauro Ferrari Director | 8,750 0.01% of outstanding | $493k | Nov 28, 2025 | none |
| Oct 1, 2025 | James Hamilton Officer | 20,000 0.01% of outstanding | $700k | Oct 1, 2025 | $1.0M |
| Sep 12, 2025 | Hamilton James C Officer | 15,000 0.01% of outstanding | $450k | Sep 12, 2025 | $575k |
| Sep 2, 2025 | Hamilton James C Officer | 15,000 0.01% of outstanding | $375k | Sep 2, 2025 | $200k |
| Aug 15, 2025 | Hamilton James C Officer | 9,389 0.01% of outstanding | $188k | Aug 15, 2025 | $12k |
Transactions
The newest 50 of 141 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Adeoye Y Olukotun director | SOpen-market sale Common Stock | -2,000 | $86.96 | $174k | 31,600 | Aug 20, 2026 |
| Aug 18, 2026 | Michael S Perry director | SOpen-market sale Common Stock | -11,600 | $87.30 | $1.0M | 111,459 | Aug 20, 2026 |
| Jun 15, 2026 | Matthew Gregory Cohen director | AGrant or award Common Stock | +11,882 | $0.00 | $0 | 11,882 | Jun 17, 2026 |
| May 12, 2026 | Hongbo Lu director | SOpen-market sale Common Stock10b5-1 | -2,970 | $76.88 | $228k | 52,012 | May 14, 2026 |
| Apr 22, 2026 | Daniel Joseph Apel Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -3,208 | $70.11 | $225k | 172,792 | Apr 24, 2026 |
| Apr 23, 2026 | James C Hamilton Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $75.00 | $750k | 226,958 | Apr 24, 2026 |
| Apr 22, 2026 | Daniel Joseph Apel Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -1,157 | $70.45 | $82k | 171,635 | Apr 24, 2026 |
| Apr 22, 2026 | Daniel Joseph Apel Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -8,730 | $71.92 | $628k | 162,905 | Apr 24, 2026 |
| Mar 5, 2026 | James C Hamilton Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $64.19 | $642k | 236,958 | Mar 9, 2026 |
| Jan 6, 2026 | James C Hamilton Chief Medical Officer | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 246,958 | Jan 8, 2026 |
| Jan 6, 2026 | Daniel Joseph Apel Chief Financial Officer | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 176,200 | Jan 8, 2026 |
| Jan 6, 2026 | Patrick O'Brien COO | GGift Common Stock | -540 | $0.00 | $0 | 474,368 | Jan 8, 2026 |
| Jan 6, 2026 | Patrick O'Brien COO | GGift Common Stock | -540 | $0.00 | $0 | 473,828 | Jan 8, 2026 |
| Jan 6, 2026 | Patrick O'Brien COO | GGift Common Stock | -540 | $0.00 | $0 | 473,288 | Jan 8, 2026 |
| Jan 6, 2026 | Patrick O'Brien COO | GGift Common Stock | -440 | $0.00 | $0 | 472,848 | Jan 8, 2026 |
| Jan 6, 2026 | Patrick O'Brien COO | GGift Common Stock | -440 | $0.00 | $0 | 472,408 | Jan 8, 2026 |
| Jan 6, 2026 | Patrick O'Brien COO | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 547,408 | Jan 8, 2026 |
| Jan 2, 2026 | Christopher Richard Anzalone Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -7,416 | $65.88 | $489k | 3,798,510 | Jan 5, 2026 |
| Dec 31, 2025 | Patrick O'Brien COO | GGift Common Stock10b5-1 | -560 | $0.00 | $0 | 526,641 | Jan 5, 2026 |
| Jan 5, 2026 | James C Hamilton Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -4,625 | $61.24 | $283k | 207,497 | Jan 5, 2026 |
| Jan 2, 2026 | Christopher Richard Anzalone Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -5,771 | $66.39 | $383k | 3,792,739 | Jan 5, 2026 |
| Dec 31, 2025 | Patrick O'Brien COO | GGift Common Stock10b5-1 | -560 | $0.00 | $0 | 526,081 | Jan 5, 2026 |
| Jan 5, 2026 | James C Hamilton Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -6,090 | $62.28 | $379k | 201,407 | Jan 5, 2026 |
| Jan 5, 2026 | James C Hamilton Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -14,792 | $63.01 | $932k | 186,615 | Jan 5, 2026 |
| Dec 31, 2025 | Patrick O'Brien COO | GGift Common Stock10b5-1 | -560 | $0.00 | $0 | 525,521 | Jan 5, 2026 |
| Jan 5, 2026 | James C Hamilton Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -12,711 | $63.95 | $813k | 173,904 | Jan 5, 2026 |
| Dec 31, 2025 | Patrick O'Brien COO | GGift Common Stock10b5-1 | -560 | $0.00 | $0 | 524,961 | Jan 5, 2026 |
| Jan 5, 2026 | James C Hamilton Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -1,200 | $64.49 | $77k | 172,704 | Jan 5, 2026 |
| Dec 31, 2025 | Patrick O'Brien COO | GGift Common Stock10b5-1 | -560 | $0.00 | $0 | 524,401 | Jan 5, 2026 |
| Jan 5, 2026 | James C Hamilton Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -437 | $65.97 | $29k | 172,267 | Jan 5, 2026 |
| Jan 5, 2026 | Patrick O'Brien COO | SOpen-market sale Common Stock10b5-1 | -4,368 | $61.20 | $267k | 520,033 | Jan 5, 2026 |
| Jan 5, 2026 | James C Hamilton Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -309 | $68.00 | $21k | 171,958 | Jan 5, 2026 |
| Jan 5, 2026 | Patrick O'Brien COO | SOpen-market sale Common Stock10b5-1 | -6,164 | $62.23 | $384k | 513,869 | Jan 5, 2026 |
| Jan 5, 2026 | Patrick O'Brien COO | SOpen-market sale Common Stock10b5-1 | -13,451 | $62.96 | $847k | 500,418 | Jan 5, 2026 |
| Jan 5, 2026 | Patrick O'Brien COO | SOpen-market sale Common Stock10b5-1 | -11,842 | $63.84 | $756k | 488,576 | Jan 5, 2026 |
| Jan 5, 2026 | Patrick O'Brien COO | SOpen-market sale Common Stock10b5-1 | -2,700 | $64.44 | $174k | 485,876 | Jan 5, 2026 |
| Jan 5, 2026 | Patrick O'Brien COO | SOpen-market sale Common Stock10b5-1 | -900 | $66.01 | $59k | 484,976 | Jan 5, 2026 |
| Jan 5, 2026 | Patrick O'Brien COO | SOpen-market sale Common Stock10b5-1 | -313 | $68.00 | $21k | 484,663 | Jan 5, 2026 |
| Jan 5, 2026 | Patrick O'Brien COO | SOpen-market sale Common Stock10b5-1 | -600 | $61.12 | $37k | 484,063 | Jan 5, 2026 |
| Jan 5, 2026 | Patrick O'Brien COO | SOpen-market sale Common Stock10b5-1 | -900 | $62.25 | $56k | 483,163 | Jan 5, 2026 |
| Jan 5, 2026 | Patrick O'Brien COO | SOpen-market sale Common Stock10b5-1 | -5,873 | $62.91 | $369k | 477,290 | Jan 5, 2026 |
| Jan 5, 2026 | Patrick O'Brien COO | SOpen-market sale Common Stock10b5-1 | -2,336 | $64.04 | $150k | 474,954 | Jan 5, 2026 |
| Jan 5, 2026 | Patrick O'Brien COO | SOpen-market sale Common Stock10b5-1 | -46 | $68.00 | $3,128 | 474,908 | Jan 5, 2026 |
| Dec 29, 2025 | Christopher Richard Anzalone Chief Executive Officer | MOption exercise Common Stock10b5-1 | +35,181 | $6.15 | $216k | 3,841,107 | Dec 30, 2025 |
| Dec 26, 2025 | Mauro Ferrari director | SOpen-market sale Common Stock10b5-1 | -7,530 | $70.00 | $527k | 69,053 | Dec 30, 2025 |
| Dec 29, 2025 | Christopher Richard Anzalone Chief Executive Officer | MOption exercise Common Stock10b5-1 | +16,545 | $6.15 | $102k | 3,857,652 | Dec 30, 2025 |
| Dec 29, 2025 | Christopher Richard Anzalone Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -35,181 | $69.33 | $2.4M | 3,822,471 | Dec 30, 2025 |
| Dec 29, 2025 | Christopher Richard Anzalone Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -16,545 | $68.69 | $1.1M | 3,805,926 | Dec 30, 2025 |
| Dec 29, 2025 | Christopher Richard Anzalone Chief Executive Officer | MOption exercise Stock Option (right to buy Common Stock)derivative10b5-1 | -35,181 | $0.00 | $0 | 16,545 | Dec 30, 2025 |
| Dec 29, 2025 | Christopher Richard Anzalone Chief Executive Officer | MOption exercise Stock Option (right to buy Common Stock)derivative10b5-1 | -16,545 | $0.00 | $0 | 0 | Dec 30, 2025 |
50 of 141 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Christopher Richard AnzaloneChief Executive Officer
- Daniel Joseph ApelChief Financial Officer
- Matthew Gregory Cohendirector
- Mauro Ferraridirector
- Douglas B Givendirector
- James C HamiltonChief Medical Officer
- Hongbo Ludirector
- Kenneth Allen MyszkowskiChief Financial Officer
- Patrick O'BrienCOO
- Adeoye Y Olukotundirector
- Michael S Perrydirector
- Victoria Vakienerdirector
- William D. Waddilldirector
Questions about ARWR
Answered from the filings on this page, as of the latest one.
Are insiders buying ARWR?
As of Aug 20, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 2 open-market sells worth $1.2M by 2 insiders at ARROWHEAD PHARMACEUTICALS, INC. in the last 90 days, net -$1.2M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade ARWR on the open market?
Adeoye Y Olukotun (director) sold $174k of ARWR on Aug 18, 2026 and filed the Form 4 on Aug 20, 2026. InsiderTell scored 34 (weak), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at ARROWHEAD PHARMACEUTICALS, INC.?
13 people have filed a Form 4 at ARROWHEAD PHARMACEUTICALS, INC., among them Christopher Richard Anzalone (Chief Executive Officer), Daniel Joseph Apel (Chief Financial Officer), Matthew Gregory Cohen (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.